KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $13.3 billion.

  • Edwards Lifesciences' Liabilities and Shareholders Equity rose 232.05% to $13.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $52.8 billion, marking a year-over-year increase of 2529.88%. This contributed to the annual value of $13.1 billion for FY2024, which is 3943.2% up from last year.
  • Per Edwards Lifesciences' latest filing, its Liabilities and Shareholders Equity stood at $13.3 billion for Q3 2025, which was up 232.05% from $13.5 billion recorded in Q2 2025.
  • Edwards Lifesciences' Liabilities and Shareholders Equity's 5-year high stood at $13.5 billion during Q2 2025, with a 5-year trough of $7.2 billion in Q1 2021.
  • For the 5-year period, Edwards Lifesciences' Liabilities and Shareholders Equity averaged around $9.9 billion, with its median value being $9.0 billion (2023).
  • In the last 5 years, Edwards Lifesciences' Liabilities and Shareholders Equity crashed by 247.1% in 2022 and then soared by 3943.2% in 2024.
  • Over the past 5 years, Edwards Lifesciences' Liabilities and Shareholders Equity (Quarter) stood at $8.5 billion in 2021, then decreased by 2.47% to $8.3 billion in 2022, then rose by 12.91% to $9.4 billion in 2023, then skyrocketed by 39.43% to $13.1 billion in 2024, then increased by 1.66% to $13.3 billion in 2025.
  • Its last three reported values are $13.3 billion in Q3 2025, $13.5 billion for Q2 2025, and $13.0 billion during Q1 2025.